Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
Benjamin Dehay(Centre National de la Recherche Scientifique), Wassilios G. Meissner(Centre National de la Recherche Scientifique), Gregory A. Petsko(Brigham and Women's Hospital), Stéphane Hunot(Centre National de la Recherche Scientifique), Philippe Gorry(Université de Bordeaux), Serge Przedborski(Columbia University), Miquel Vila(Institució Catalana de Recerca i Estudis Avançats), Kalpana Merchant(Pfizer (United States)), Mathieu Bourdenx(University of Suffolk), C. Warren Olanow(Icahn School of Medicine at Mount Sinai), Andrew Singleton(Short and Associates (United States)), Erwan Bézard(Centre National de la Recherche Scientifique)
Cited by 508
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
The Parkinson Progression Marker Initiative (PPMI)
|Progress in Neurobiology|2011|1.9k